AACR 2023 | The future of immune checkpoint inhibition in melanoma

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, talks on novel developments in the field of immune checkpoint blockade in melanoma. In addition to existing PD-1 blockade, TIGIT, TIM-3 and LAG-3 have all been identified as promising targets. These targets have potential to be used with existing inhibitors such as nivolumab, and Dr Weber additionally highlights the growing role of bispecific antibodies. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.